DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist.
CAT No: R1322
CAS No:78123-71-4
Synonyms/Alias:DAMGO;DAGO;78123-71-4;glyol;Dagol;DAMGE;2-Ala-4-mephe-5-gly-enkephalin;Tyr-ala-gly-(nme)phe-gly-ol;RX 783006;(D-Ala(2)-mephe(4)-gly-ol(5))enkephalin;(2S)-2-amino-N-[(2R)-1-[[2-[[(2S)-1-(2-hydroxyethylamino)-1-oxo-3-phenylpropan-2-yl]-methylamino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide;Enkephalin, ala(2)-mephe(4)-gly(5)-;CHEBI:272;CHEMBL38874;Tyr-D-Ala-Gly-MePhe-Gly-ol;Enkephalin, alanyl(2)-methylphenylalanyl(4)-glycine(5)-;950492-85-0;[3H]DAMGO;Tyr-D-Ala-Gly-MePhe-Gly(ol);Tyr-D-Ala-Gly-NMe-Phe-Gly-ol;Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol;Tyr-D-Ala-Gly-N(Me)Phe-Gly-ol;Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol;Ala(2)-mephe(4)-gly-ol(5) enkephalin;Tyr-D-Ala-Gly-N-Methyl-Phe-Gly-ol;D-Ala2-MePhe4-Met(0)5-enkephalin-ol;Enkephalin, Ala(2)-MePhe(4)-Gly-ol(5)-;C26H35N5O6;H-Tyr-D-Ala-Gly-N-Me-Phe-Glycinol;[D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin;2YM5VT3MNR;RX783006;Dagol;L-Phenylalaninamide, L-tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nalpha-methyl-;Tyr-DAla-Gly-MePhe-Gly-ol;SCHEMBL725750;GTPL1647;Tyr-D-Ala-Gly-NMePhe-Gly-ol;BDBM21015;H-Tyr-D-Ala-Gly-MePhe-Gly-ol;Tyr-D-Ala2-Gly-NMePhe-Gly-ol;DTXSID30228775;HPZJMUBDEAMBFI-WTNAPCKOSA-N;HY-P0210;Tyr-D-Ala-Gly-N(CH3)Phe-Gly-ol;H-Tyr-D-Ala-Gly-N(Me)Phe-Gly-ol;HB2409;AKOS024456435;NCGC00167303-01;(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]-methylamino]-N-(2-hydroxyethyl)-3-phenylpropanamide;AS-83278;BD173150;BD174973;DA-72545;CS-0021316;G12226;Q5204254;[tyrosyl-3,5-3H(N)]-D-Ala2-Mephe4-glyol5-enkephalin;3: PN: WO2009046859 PAGE: 98 CLAIMED PROTEIN;158: PN: US20030176421 PAGE: 54-55 CLAIMED PROTEIN;L-TYROSYL-D-ALANYLGLYCYL-N-(2-HYDROXYETHYL)-N.ALPHA.-METHYL-L-PHENYLALANINAMIDE;L-Tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nalpha-methyl-L-phenylalaninamide;(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-N-methylacetamido}-N-(2-hydroxyethyl)-3-phenylpropanamide;(2S)-2-amino-N-[(1R)-2-[[2-[[(1S)-1-benzyl-2-(2-hydroxyethylamino)-2-oxo-ethyl]-methyl-amino]-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethyl]-3-(4-hydroxyphenyl)propanamide;(S)-2-amino-N-((R)-1-(2-(((S)-1-(2-hydroxyethylamino)-1-oxo-3-phenylpropan-2-yl)(methyl)amino)-2-oxoethylamino)-1-oxopropan-2-yl)-3-(4-hydroxyphenyl)propanamide;Benzenepropanimidic?acid, .alpha.-amino-4-hydroxy-N-[(1R,2Z)-2-hydroxy-2-[[2-[[(1S,2Z)-2-hydroxy-2-[(2-hydroxyethyl)imino]-1-(phenylmethyl)ethyl]methylamino]-2-oxoethyl]imino]-1-methylethyl]-, (.alpha.S)-;
3. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
5. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More